Hepatitis C (HCV) infection is prevalent in recipients of, and candidates for, solid organ transplants. The outcomes of HCV infection in cardiac and lung transplant recipients have yet to be clearly established, and future prospective studies are needed. In the absence of safe and effective antiviral treatment for HCV infection in heart and lung transplant recipients, the management of these patients remains a challenge and must be considered on an individual basis. Interferon therapy for HCV before transplantation appears to improve outcomes; however, post-transplant interferon therapy in the cardiac and pulmonary transplant setting may be associated with an increased risk of graft rejection. Given the paucity of information regarding HCV treatment in these transplant recipients, and with appropriate concerns that graft loss from rejection may not be amenable to a second transplant (given the scarcity of suitable cadaveric organs), multicentre, randomized controlled trials are needed to determine the optimal approach for treatment of HCV infection in this population.

Key Words: Heart; Hepatitis C; Interferon; Lung; Rejection; Transplant; Treatment

**PRE-EXISTING HCV INFECTION IN CARDIAC TRANSPLANTATION**

There are limited studies addressing the outcome of pre-existing HCV infection in heart transplant (HT) recipients. Despite the reluctance of many centres to perform HT in HCV-positive (HCV+) patients, pre-existing HCV infection has not been clearly shown to increase all-cause mortality among HT recipients. A retrospective study with 96 HCV+ HT recipients (1) reported no difference in mortality rates, but an increased incidence of liver-related deaths when compared with uninfected patients. A more recent study followed 11 patients with pre-existing chronic HCV for a mean of 32 months (2), and evaluated liver function laboratory parameters, pre- and postsurgical hepatobiliary ultrasound examinations performed before or after heart transplantation. There were three deaths (27%), none of which were related to HCV infection. No morphological or laboratory abnormalities were observed to suggest reactivation of the infection during the follow-up period. However, a six-year follow-up evaluation of 36 HCV+ HT recipients (3) reported that 21 patients (58%) developed ‘chronic liver disease’, defined as liver enzyme levels greater than 1.5 times the upper limit of normal, with clinically relevant cirrhosis in 28%. Three of these six cirrhotic patients, all with de novo HCV infection, died of end-stage liver disease at a mean of six years after heart transplantation. A recent study assessed the clinical outcomes of 224 HCV-seropositive HT recipients (4), and found reduced survival rates compared with their HCV-negative counterparts. However, the adjusted RR of recipient HCV-seropositive versus HCV-seronegative status did not reach statistical significance after adjusting for other donor and recipient factors. There was also no statistically significant difference in acute rejection episodes in the first year after transplantation between the two groups.

Can J Gastroenterol Vol 25 No 8 August 2011

©2011 Pulsus Group Inc. All rights reserved
DE NOVO HCV INFECTION AFTER CARDIAC TRANSPLANTATION

Transplantation of HCV antibody-positive donor organs into uninfected recipients almost uniformly results in chronic HCV infection in the immunocompromised host, with reported transmission rates ranging from 7% to 82% (5-7). However, most of these studies were limited by the lack of serum HCV RNA testing in the cadaveric donors at the time of organ procurement. Reportedly, almost one-third of HT recipients with HCV infection have an undetectable level of anti-HCV antibodies as a consequence of their immunocompromised state (5,6,8,9). Furthermore, Lunel et al (10) showed that patients with de novo HCV infection following cardiac transplantation have a significant delay between elevation of aminotransferases levels or HCV RNA detection and anti-HCV detection. In addition to the substantial risk of HCV transmission to the transplant recipient, high rates of subsequent liver enzyme abnormalities have been reported (6). Many patients who acquired HCV in the peri- or post-transplant period developed chronic hepatitis, with more severe liver disease found in those infected with hepatitis B virus (HBV) and HCV (3,11).

Marelli et al (7) reported HCV transmission in only 25% of HT recipients under similar circumstances. In contrast, a prospective study by Ong et al (5), found that 23 of 28 recipients (82%) of donor HCV+ hearts became HCV RNA positive. Seven of these patients (30%) developed HCV-related liver disease, four progressing to severe cholestatic hepatitis. Risk factors for severe hepatitis included the use of mycophenolate mofetil and high HCV viral load. However, overall survival was similar to that seen in a matched control HCV-negative donor population, without significant short-term differences in the rate of fibrosis progression when compared with immunocompetent patients with HCV infection. Several small studies also found that de novo HCV infection did not appear to reduce both short-term and intermediate-term survival after cardiac transplantation (5,10) (Table 1).

However, development of acute cholestatic hepatitis and mycophenolate use have been independently associated with increased mortality in patients with de novo HCV infection (5,12). In addition, mortality among 34 recipients of HCV+ donor hearts was 2.8-fold (95% CI 1.3 to 5.9) greater than controls at the Cleveland Clinic (USA) (13). More recently, a multicentre cohort study was performed to assess all-cause mortality in 261 patients who received an HCV+ donor heart (14). Mortality was higher among recipients of HCV+ donor hearts at one, five and 10 years, who were more likely to die of liver disease and coronary vasculopathy, independent of recipient HCV status or age.

TREATMENT OF HCV IN A CARDIAC TRANSPLANT POPULATION

In 1998, Fagguoli et al (15) reported treatment of three HT recipients with chronic HCV infection with interferon (IFN) (5 million units of IFN-alpha three times per week) without development of acute cellular rejection during therapy. A few years later, the same investigators treated five HT recipients with chronic HCV and one with combined HBV/HCV chronic infection (16). The mean (± SD) follow-up after HT was 8.5±3 years, and the patients received natural leukocyte IFN (IFN-alpha-N3) at a dose of 6 million units intramuscularly three times per week for 12 months. Follow-up continued for at least 12 months after treatment. All patients completed the treatment with no major side effects. The patient with combined HBV/HCV infection showed complete biochemical and virological responses (ie, the HBV DNA and HCV RNA were negative at the third month). Sustained response was achieved over a 12-month follow-up. Of the four HT recipients with chronic HCV infection, three (75%) exhibited sustained biochemical responses after a 12-month follow-up period. In addition, HCV RNA was negative in three patients by the third month of treatment; however, virological response was not sustained at the end of IFN treatment and during follow-up. A recent case report (17) documented a fatality after IFN/ribavirin treatment for chronic HCV in a 50-year-old orthopitic HT recipient transplanted for ischemic cardiomyopathy. Elevated liver enzyme levels one year after heart transplantation (alanine aminotransferase 246 U/L; aspartate aminotransferase 123 U/L) were attributed to pre-existing HCV infection in the setting of immunosuppression. Liver biopsy revealed chronic hepatitis with moderate fibrosis and mild activity. HCV was treated with pegylated IFN-2b and ribavirin for six months, with liver enzyme results gradually returning to the normal range. At that time, ribavirin was discontinued while pegylated IFN was continued. The patient ultimately presented with severe heart failure and succumbed to arrhythmia refractory to medical treatment. At autopsy, the patient was found to have patent coronary arteries, diffuse severe fatty degeneration of heart myocytes, and no evidence of cellular or humoral rejection, which was believed to be confirmatory of cardiotoxicity from pegylated IFN alpha-2b.

Aside from antiviral therapy, other agents, such as ursodeoxycholic acid (ursodiol), have also been evaluated for treatment of chronic viral hepatitis in the HT population. Several studies, including a meta-analysis (18), have reported the beneficial effect of ursodiol on liver biochemistry in patients with chronic hepatitis. In 2003, however, a double-blind randomized controlled trial by Cadranell et al (19) concluded that a one-year course of ursodiol did not have any effect on liver biochemistry or histology in HT patients with chronic HCV.

In summary, although two small pilot studies demonstrated that IFN monotherapy might be effective and well-tolerated in the treatment of HCV in HT recipients, further studies are still needed to assess the efficacy of IFN-based antiviral therapy in this population. As in renal allograft recipients, IFN-based antiviral therapy may place HT recipients at a higher risk of graft rejection allograft failure from cardiotoxicity. The adverse effect profile of the combination of IFN and ribavirin can also affect the tolerability of these medications. Given these limitations, development of more effective treatments with improved side effect profiles is needed.

HCV IN LUNG TRANSPLANT RECIPIENTS

There are limited data regarding outcomes after lung transplantation in recipients with pre-existing or de novo HCV infection. In 1998, Cotler et al (20) surveyed all United Network of Organ Sharing-approved lung transplant centres in the United States to evaluate practices regarding HCV-infected donors, recipients and to gather preliminary data on the outcomes of lung transplant recipients with HCV. This survey study revealed that all programs screened potential organ donors and lung transplant candidates for HCV using antibody testing. When it came to policies regarding transplantation of HCV-infected candidates, they determined that 33 of 46 (72%) programs considered HCV-infected candidates for transplantation, while 26 of 47 (55%) accepted lung allografts from seropositive donors. In addition, eight of 48 (17%) had transplanted lung allografts from seropositive donors into uninfected recipients. However, the survey indicated that post-transplant monitoring of patients with HCV varied significantly. Biochemical evidence of hepatitis was noted following transplantation in six of 14 HCV donor-positive/recipient-negative cases; however, no verifiable HCV-related deaths were reported in lung transplant recipients in any of these cases. The progression of liver injury in patients with HCV following lung transplantation could not be evaluated due to incomplete histological data. The authors concluded that more studies were needed to evaluate outcomes of HCV-infected lung transplant recipients. However, in 2001, Carrero et al (21) presented a small case series of three patients who acquired HCV after lung transplantation. All three patients developed elevated liver enzyme levels post-lung transplantation which ultimately led to the diagnosis of HCV. Each of these patients had high viral loads and were infected with genotype 1b. All died within one year of transplant; two died of hepatic failure despite treatment and one died from hemoptysis due to fungal infection. The authors concluded that in lung transplant recipients, post-transplant HCV infection portended a poor prognosis.
Conversely, a small retrospective cohort study by Sahi et al (22) did not find any significant difference in patient or graft survival between HCV+ lung transplant recipients and HCV-negative recipients. Six patients were identified to be HCV+ before lung transplantation. Marked increase in HCV RNA levels were found post-transplant, but without concomitant increases in transaminase levels. No significant increase in acute rejection was found in the first year post-transplantation. Three deaths (27%), more likely to die of liver disease and coronary vasculopathy, were observed. No abnormalities were observed on liver ultrasounds performed serially after transplantation. Three deaths (27%), unrelated to HCV. No morphological or laboratory abnormalities were observed to suggest reactivation of HCV during follow-up. One patient completed 48 weeks of therapy for genotype 1 HCV infection and, despite a negative HCV RNA at week 12, her end-of-treatment response (HCV-RNA negative), was 2.2 L (62% predicted) seven months post-transplant. The fifth patient was awaiting transplant (23). Although it has been suggested that lung transplant candidates would be poor candidates for HCV treatment because most hepatologists in the nontransplant setting would be very reluctant to offer treatment to patients with end-stage liver disease, this small study suggested that this population could be acceptable transplant candidates.

In 2007, Doucette et al (23) described the outcomes of HCV treatment in five lung transplant candidates, modelled on the suggested approach to HCV-infected renal transplant candidates. Patients were identified after referral for lung transplant assessment who were HCV antibody and HCV RNA positive, and otherwise acceptable transplant candidates. These patients were determined to be candidates for HCV therapy based on ‘published guidelines’. Five patients were treated with standard HCV therapy at time of presentation: ribavirin plus either IFN-alpha 2b or pegylated IFN alpha-2b for 24 (genotype 3) or 48 weeks (genotype 1). During treatment, all patients experienced the anticipated adverse effects of IFN and ribavirin (eg, flu-like symptoms, anemia and mild leukopenia). One patient discontinued treatment due to anxiety, which the authors believed was IFN related. Three patients exhibited sustained virological response, and one patient underwent uncomplicated lung transplant with immunosuppression using cyclosporine, mycophenolate mofetil and prednisone. At nine months, post-transplant rejection was clinically diagnosed after an upper respiratory tract infection and the patient was treated with methylprednisolone. At 21 months post-transplant, she continued to exhibit excellent lung function with a forced expiratory volume in 1 s (FEV₁) of 2.01 L (69% predicted); her HCV-RNA remains negative with normal liver enzyme levels and liver function. Another patient experienced an end-of-treatment response (HCV-RNA negative), but relapsed with a positive HCV RNA six months after completing therapy. Liver biopsy showed only moderate disease, and he subsequently underwent lung transplant. He experienced two episodes of rejection, one responding to methylprednisolone, and one requiring thymoglobulin. Liver enzyme levels remained normal, and his FEV₁ was 2.2 L (62% predicted) seven months post-transplant. The fifth patient completed 48 weeks of therapy for genotype 1 HCV infection and, despite a negative HCV-RNA at week 12, her end-of-treatment HCV-RNA was positive. Liver biopsy showed only mild disease; this patient was awaiting transplant (23). Although it has been suggested that lung transplant candidates would be poor candidates for HCV treatment because most hepatologists in the nontransplant setting would be very reluctant to offer treatment to patients with end-stage liver disease, this small study suggested that this population could be treated for HCV safely and effectively. The authors concluded that it may be inappropriate to exclude otherwise acceptable lung transplant candidates on the basis of HCV infection as recommended by the 2006 international guidelines for the selection of lung transplant candidates (24).

Currently, robust clinical studies regarding the outcomes of chronic HCV infection, and the safety and efficacy of IFN-based HCV therapy in lung transplant recipients have not been reported and additional definitive studies are required. The potential adverse effects of antiviral therapy and the risk of graft rejection would have to be carefully considered and might outweigh the benefit of antiviral therapy for HCV in this population.
**SUMMARY**

Hepatitis C infection is prevalent in recipients of, and candidates for, solid organ transplants. The outcomes of HCV in recipients of cardiac and lung transplants have yet to be clearly established, and future prospective studies are needed. In the absence of safe and effective antiviral treatment for HCV infection in HT and lung transplant recipients, the management of these patients remains a challenge and must be considered on an individual basis. There is limited published experience with IFN therapy for HCV before cardiac transplantation, which may be limited by the concerns regarding safety and tolerability of IFN and ribavirin in this population. Furthermore, post-transplant IFN therapy in the cardiac and pulmonary transplant setting may be associated with an increased risk of graft rejection. Given the paucity of information on HCV treatment in these transplant recipients, and with appropriate concerns that graft loss from rejection may not be amenable to a second transplant (given the scarcity of suitable cadaveric organs), multi-centre, randomized controlled trials are needed to determine the optimal approach for treatment of HCV infection in this population.

**REFERENCES**

Submit your manuscripts at http://www.hindawi.com